	US 12,240,912 B1
	Methods of treating complement-mediated disease
Nick Stub Laursen, Aarhus C (DK); Dennis Vestergaard Pedersen, Aarhus C (DK); Gregers Rom Andersen, Brabrand (DK); Steffen Thiel, Risskov (DK); Alessandra Zarantonello, Aarhus C (DK); Rasmus Kjeldsen Jensen, Aarhus C (DK); and Henrik Pedersen, Aarhus C (DK)
Assigned to Aarhus Universitet, Aarhus C (DK)
Filed by Aarhus Universitet, Aarhus C (DK)
Filed on Mar. 27, 2024, as Appl. No. 18/618,634.
Application 18/618,634 is a continuation of application No. 17/251,023, granted, now 12,110,321, previously published as PCT/EP2019/065206, filed on Jun. 11, 2019.
Claims priority of application No. 18176954 (EP), filed on Jun. 11, 2018.
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)]

20 Claims

1. A method of generating a cancer cell-targeted, complement-mediated immunological response in a subject, the method comprising:

administering to the subject an effective amount of a polypeptide that comprises:

(a) a human C1q complement factor-binding V_HH domain; and

(b) a target-binding moiety that binds to a cancer-specific marker expressed on said cancer cell,

wherein the polypeptide, upon binding to a surface and the human C1q complement factor, activates a classical complement system, and wherein said administration results in complement-mediated clearance of cancer cells in the subject upon such activation of the classical complement system.